Drug Interactions between Envarsus XR and mycophenolic acid
This report displays the potential drug interactions for the following 2 drugs:
- Envarsus XR (tacrolimus)
- mycophenolic acid
Interactions between your drugs
No interactions were found between Envarsus XR and mycophenolic acid. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Envarsus XR
A total of 867 drugs are known to interact with Envarsus XR.
- Envarsus xr is in the drug class calcineurin inhibitors.
- Envarsus xr is used to treat Organ Transplant, Rejection Prophylaxis.
mycophenolic acid
A total of 338 drugs are known to interact with mycophenolic acid.
- Mycophenolic acid is in the drug class selective immunosuppressants.
-
Mycophenolic acid is used to treat the following conditions:
- Dermatomyositis (off-label)
- Rejection Prophylaxis
Drug and food interactions
tacrolimus food
Applies to: Envarsus XR (tacrolimus)
ADJUST DOSING INTERVAL: Consumption of food has led to a 27% decrease in the bioavailability of orally administered tacrolimus.
MANAGEMENT: Tacrolimus should be administered at least one hour before or two hours after meals.
GENERALLY AVOID: Grapefruit juice has been reported to increase tacrolimus trough concentrations. Data are limited, but inhibition of the CYP450 enzyme system appears to be involved.
MANAGEMENT: The clinician may want to recommend that the patient avoid ingesting large amounts of grapefruit juice while taking tacrolimus.
References (2)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
mycophenolic acid food
Applies to: mycophenolic acid
ADJUST DOSING INTERVAL: Administration of enteric coated mycophenolic acid with meals may alter its pharmacokinetics relative to administration in the fasting state. When mycophenolic acid 720 mg was administered with a high-fat meal, there was a 33% decrease in the peak plasma concentration (Cmax); a 3.5-hour increase in delay time for the rise of plasma mycophenolic acid; and a 5-hour delay in the time to reach peak plasma concentration (Tmax). However, no effect was observed on the systemic exposure of mycophenolic acid.
MANAGEMENT: To avoid variability in drug absorption between doses, enteric coated formulations of mycophenolic acid should be taken on an empty stomach, one hour before or two hours after food intake. The tablets should be swallowed whole and not crushed, chewed or divided in order to maintain the integrity of the enteric coating.
References (1)
- (2004) "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.